Cargando…

Varicella-zoster virus seroprevalence in children and adolescents in the pre-varicella vaccine era, Germany

BACKGROUND: In 2004, universal childhood varicella vaccination was introduced in Germany. We aimed to determine the age-specific prevalence of anti-varicella zoster virus (VZV) IgG-antibodies among children in the pre-varicella vaccine era in Germany, to identify factors associated with VZV seroposi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wiese-Posselt, Miriam, Siedler, Anette, Mankertz, Annette, Sauerbrei, Andreas, Hengel, Hartmut, Wichmann, Ole, Poethko-Müller, Christina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5438501/
https://www.ncbi.nlm.nih.gov/pubmed/28525973
http://dx.doi.org/10.1186/s12879-017-2461-2
_version_ 1783237775242297344
author Wiese-Posselt, Miriam
Siedler, Anette
Mankertz, Annette
Sauerbrei, Andreas
Hengel, Hartmut
Wichmann, Ole
Poethko-Müller, Christina
author_facet Wiese-Posselt, Miriam
Siedler, Anette
Mankertz, Annette
Sauerbrei, Andreas
Hengel, Hartmut
Wichmann, Ole
Poethko-Müller, Christina
author_sort Wiese-Posselt, Miriam
collection PubMed
description BACKGROUND: In 2004, universal childhood varicella vaccination was introduced in Germany. We aimed to determine the age-specific prevalence of anti-varicella zoster virus (VZV) IgG-antibodies among children in the pre-varicella vaccine era in Germany, to identify factors associated with VZV seropositivity, and to assess the suitability of a commercially available ELISA for VZV seroepidemiological studies by comparing it with an in-house fluorescent antibody to membrane antigen test (FAMA) as the gold standard. METHODS: Serum samples of 13,433 children and adolescents aged 1–17 years included in the population-based German Health Interview and Examination Survey for Children and Adolescents (KiGGS; conducted 2003–2006) were tested for anti-VZV IgG by ELISA. All samples with equivocal ELISA results and a random selection of ELISA-negative and -positive samples were tested by FAMA. Statistical analyses were conducted using a weighting factor adjusting the study population to the total population in Germany. Seroprevalences were calculated as percentages (%) with a 95% confidence interval (CI). Odds ratios (OR) were computed by multivariate logistic regression to determine the association between socio-demographic factors and VZV seropositivity. RESULTS: The VZV seropositivity rate was 80.3% (95% CI: 79.3–81.3) in varicella-unvaccinated children and adolescents. VZV seropositivity rates differed significantly between age groups up to age 6 years, but not by gender. Of 118 retested serum samples with an equivocal ELISA result, 45.8% were FAMA-positive. The proportion of samples tested as false-negative in by ELISA varied by age group: 2.6% in children aged 1–6 and 9% in children aged 7–17 years. Multivariate analyses showed that age, having older siblings, and early daycare start were associated with seropositivity in preschoolers; migration background reduced the chance of VZV seropositivity in schoolchildren (OR: 0.65; 0.43–0.99) and adolescents (OR: 0.62; 0.4–0.97). CONCLUSION: In the pre-varicella vaccine era, most children in Germany contracted varicella by age six. Schoolchildren with a migration background and children without siblings have an increased risk of being VZV seronegative and should be targeted for catch-up vaccination, if they have no history of chickenpox. ELISAs are suitable for use in population-level serosurveys on VZV, but samples with equivocal ELISA results should be retested by FAMA.
format Online
Article
Text
id pubmed-5438501
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-54385012017-05-22 Varicella-zoster virus seroprevalence in children and adolescents in the pre-varicella vaccine era, Germany Wiese-Posselt, Miriam Siedler, Anette Mankertz, Annette Sauerbrei, Andreas Hengel, Hartmut Wichmann, Ole Poethko-Müller, Christina BMC Infect Dis Research Article BACKGROUND: In 2004, universal childhood varicella vaccination was introduced in Germany. We aimed to determine the age-specific prevalence of anti-varicella zoster virus (VZV) IgG-antibodies among children in the pre-varicella vaccine era in Germany, to identify factors associated with VZV seropositivity, and to assess the suitability of a commercially available ELISA for VZV seroepidemiological studies by comparing it with an in-house fluorescent antibody to membrane antigen test (FAMA) as the gold standard. METHODS: Serum samples of 13,433 children and adolescents aged 1–17 years included in the population-based German Health Interview and Examination Survey for Children and Adolescents (KiGGS; conducted 2003–2006) were tested for anti-VZV IgG by ELISA. All samples with equivocal ELISA results and a random selection of ELISA-negative and -positive samples were tested by FAMA. Statistical analyses were conducted using a weighting factor adjusting the study population to the total population in Germany. Seroprevalences were calculated as percentages (%) with a 95% confidence interval (CI). Odds ratios (OR) were computed by multivariate logistic regression to determine the association between socio-demographic factors and VZV seropositivity. RESULTS: The VZV seropositivity rate was 80.3% (95% CI: 79.3–81.3) in varicella-unvaccinated children and adolescents. VZV seropositivity rates differed significantly between age groups up to age 6 years, but not by gender. Of 118 retested serum samples with an equivocal ELISA result, 45.8% were FAMA-positive. The proportion of samples tested as false-negative in by ELISA varied by age group: 2.6% in children aged 1–6 and 9% in children aged 7–17 years. Multivariate analyses showed that age, having older siblings, and early daycare start were associated with seropositivity in preschoolers; migration background reduced the chance of VZV seropositivity in schoolchildren (OR: 0.65; 0.43–0.99) and adolescents (OR: 0.62; 0.4–0.97). CONCLUSION: In the pre-varicella vaccine era, most children in Germany contracted varicella by age six. Schoolchildren with a migration background and children without siblings have an increased risk of being VZV seronegative and should be targeted for catch-up vaccination, if they have no history of chickenpox. ELISAs are suitable for use in population-level serosurveys on VZV, but samples with equivocal ELISA results should be retested by FAMA. BioMed Central 2017-05-19 /pmc/articles/PMC5438501/ /pubmed/28525973 http://dx.doi.org/10.1186/s12879-017-2461-2 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Wiese-Posselt, Miriam
Siedler, Anette
Mankertz, Annette
Sauerbrei, Andreas
Hengel, Hartmut
Wichmann, Ole
Poethko-Müller, Christina
Varicella-zoster virus seroprevalence in children and adolescents in the pre-varicella vaccine era, Germany
title Varicella-zoster virus seroprevalence in children and adolescents in the pre-varicella vaccine era, Germany
title_full Varicella-zoster virus seroprevalence in children and adolescents in the pre-varicella vaccine era, Germany
title_fullStr Varicella-zoster virus seroprevalence in children and adolescents in the pre-varicella vaccine era, Germany
title_full_unstemmed Varicella-zoster virus seroprevalence in children and adolescents in the pre-varicella vaccine era, Germany
title_short Varicella-zoster virus seroprevalence in children and adolescents in the pre-varicella vaccine era, Germany
title_sort varicella-zoster virus seroprevalence in children and adolescents in the pre-varicella vaccine era, germany
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5438501/
https://www.ncbi.nlm.nih.gov/pubmed/28525973
http://dx.doi.org/10.1186/s12879-017-2461-2
work_keys_str_mv AT wieseposseltmiriam varicellazostervirusseroprevalenceinchildrenandadolescentsintheprevaricellavaccineeragermany
AT siedleranette varicellazostervirusseroprevalenceinchildrenandadolescentsintheprevaricellavaccineeragermany
AT mankertzannette varicellazostervirusseroprevalenceinchildrenandadolescentsintheprevaricellavaccineeragermany
AT sauerbreiandreas varicellazostervirusseroprevalenceinchildrenandadolescentsintheprevaricellavaccineeragermany
AT hengelhartmut varicellazostervirusseroprevalenceinchildrenandadolescentsintheprevaricellavaccineeragermany
AT wichmannole varicellazostervirusseroprevalenceinchildrenandadolescentsintheprevaricellavaccineeragermany
AT poethkomullerchristina varicellazostervirusseroprevalenceinchildrenandadolescentsintheprevaricellavaccineeragermany